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Cyclo19,31[D-Cys19]-uPA19-31 Is a Potent Competitive
Antagonist of the Interaction of Urokinase-Type
Plasminogen Activator with Its Receptor (CD87)
fragment. Cyclo19,31[D-Cys19]-uPA19-31 not only blocks
binding of uPA to uPAR but is also capable of effi-
ciently displacing uPAR-bound uPA from the cell sur-
face and to inhibit uPA-mediated, tumor cell-associ-
ated plasminogen activation and fibrin degradation.
Thus, cyclo19,31[D-Cys19]-uPA19-31 represents a prom-
ising therapeutic agent to significantly affect the tu-
mor-associated uPA/uPAR-system.
Key words: D-amino acid /Peptides /Protease /
Receptor /Tumor invasion /Urokinase.
Introduction
The serine proteases urokinase-type plasminogen acti-
vator (uPA) and plasmin, in concert with other proteolytic
enzymes (e. g. matrix metalloproteases, cysteine pro-
teases), are involved in tumor-associated processes
such as cell invasion and regulation of cell/cell and
cell/matrix contacts (Reuning et al., 1998; Schmitt et al.,
2000; Andreasen et al., 2000). (pro-)uPA binds to a spe-
cific, high-affinity cell surface receptor, uPAR (CD87),
which is composed of three structurally homologous, in-
dependently folded domains (Dear and Medcalf, 1998).
In addition, there are also cellular binding sites for plas-
min(ogen) (Félez, 1998). In consequence, binding of (pro-)
uPA to cell membrane-anchored uPAR significantly in-
creases plasmin generation due to a distinct increase of
reciprocal activation of pro-uPA and plasminogen (Ellis et
al., 1991). Plasmin not only degrades a variety of compo-
nents of the extracellular matrix (e. g. fibrin and laminin),
but also activates certain matrix metalloproteases (in ad-
dition to pro-uPA) which break down additional structural
proteins of the extracellular matrix such as various colla-
gens. Thus, cell surface-triggered plasminogen activa-
tion plays a fundamental role in tissue remodeling, which
is a prerequisite for tumor cell invasion and metastasis
(Reuning et al., 1998; Schmitt et al., 2000; Andreasen et
al., 2000).
The interaction of pro-uPA or its activated form high
molecular weight (HMW-)uPA with uPAR has been char-
acterised in detail. Although the N-terminal domain I of
uPAR contains major determinants for uPA-binding, high
affinity interaction with uPA is dependent on the mul-
tidomain structure of the receptor, indicating that all
three protein domains are involved in the formation of a
composite ligand binding site (Ploug, 1998; Gårdsvoll et
al., 1999; Bdeir et al., 2000). In contrast, uPA binds
to uPAR via a defined continuous peptide sequence
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Urokinase-type plasminogen activator (uPA) repre-
sents a central molecule in pericellular proteolysis
and is implicated in a variety of physiological and
pathophysiological processes such as tissue remod-
elling, wound healing, tumor invasion, and metasta-
sis. uPA binds with high affinity to a specific cell sur-
face receptor, uPAR (CD87), via a well defined
sequence within the N-terminal region of uPA (uPA19-31).
This interaction directs the proteolytic activity of uPA
to the cell surface which represents an important
step in tumor cell proliferation, invasion, and metas-
tasis. Due to its fundamental role in these proces-
ses, the uPA/uPAR-system has emerged as a novel
target for tumor therapy. Previously, we have identi-
fied a synthetic, cyclic, uPA-derived peptide, cy-
clo19,31uPA19-31, as a lead structure for the develop-
ment of low molecular weight uPA-analogues,
capable of blocking uPA/uPAR-interaction [Bürgle et
al., Biol. Chem. 378 (1997), 231 – 237]. We now
searched for peptide variants of cyclo19,31uPA19-31 with
elevated affinities for uPAR binding. Among other
tasks, we performed a systematic D-amino acid scan
of uPA19-31, in which each of the 13 L-amino acids
was individually substituted by the corresponding 
D-amino acid. This led to the identification of cy-
clo19,31[D-Cys19]-uPA19-31 as a potent inhibitor of
uPA/uPAR-interaction, displaying only a 20 to 40-fold
lower binding capacity as compared to the naturally
occurring uPAR-ligands uPA and its amino-terminal
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(uPA19 – 31) within the N-terminal region of uPA. Original-
ly, the uPAR-binding epitope of uPA was identified by
applying a linear peptide spanning amino acids 12 – 32
of uPA (in which, for technical reasons, Cys19 was sub-
stituted by Ala) in competition experiments (Appella et
al., 1987). This peptide was found to inhibit binding of
the amino-terminal fragment (ATF) of uPA (which binds
to uPAR with the same affinity as uPA but lacks the uPA
protease domain) to cell surface uPAR. Later, several lin-
ear peptides spanning uPA14-32 were synthesised in
which the naturally occurring amino acids were individu-
ally replaced by alanine (Ala scan) in order to identify the
amino acids critical for binding to uPAR (Magdolen et al.,
1996). The exchange of Cys19, Lys23, Tyr24, Phe25,
Ile28, Trp30, and Cys31, respectively, by Ala resulted in
peptides with strongly impaired uPAR-binding capaci-
ties, whereas replacement of the other amino acids had
no or little effect on uPAR binding. Finally, the minimal
uPAR-binding region of uPA was located to uPA19-31 us-
ing synthetic peptides which were successively short-
ened from the amino- and/or carboxy-terminus starting
with uPA10-32 (Bürgle et al., 1997).
The region between amino acids Thr18 and Asn32 of
uPA consists of a flexible, seven-residue Ω-loop (Asn22
to Ile28) which by means of a double stranded, antiparal-
lel ß-sheet (between Thr18 to Ser21 and His29 to Asn32)
is forced into a ring-like structure (Hansen et al., 1994a, b;
Magdolen et al., 1996; Schmitt et al., 2000). In uPA,
Cys19 and Cys31, although in close proximity, form
disulfide bonds with distinct cysteines (Cys11/Cys19 and
Cys13/Cys31, respectively; Hansen et al., 1994a, b). The
short distance between Cys19 and Cys31 in the native
molecule may explain why peptide cyclo19,31uPA19-31 with
its ‘illegitime’ disulfide bond retains or displays an even
increased uPAR-binding activity (Bürgle et al., 1997). Re-
cently, we successfully generated double-headed in-
hibitors directed at different tumor-associated proteolyt-
ic systems by exchanging a disulfide-linked loop in
cystatin, which is non-essential for cysteine protease in-
hibition, with uPA19-31. The results obtained indicate that
cystatins with a uPAR-binding site are efficient inhibitors
of cysteine proteases and uPA/uPAR-interaction at the
same time (Muehlenweg et al., 2000).
Other types of peptide antagonists of uPA/uPAR-in-
teraction, which show no obvious similarity to uPA19-31,
have been identified by a bacteriophage peptide display
approach (Goodson et al., 1994). All of the reactive pep-
tides (with the clone 20 peptide being most active) har-
bor relatively short common motifs, such as LWXXY and
FXXYLW, which may represent a variation of the motif
24YFXXIXW30 within the uPA molecule (only the critical
hydrophobic amino acids for uPAR-binding are depict-
ed) (Magdolen et al., 1996; Bürgle et al., 1997). Recent-
ly, a non-competitive, allosteric antagonist of pro-
uPA/uPAR-interaction (Å6-peptide) derived from a
non-receptor binding region of uPA (uPA136-143) has been
identified (Guo et al., 2000). As demonstrated in various
experimental in vivo model systems for competitive in-
hibitors of uPA/uPAR-interaction (Crowley et al., 1993;
Min et al., 1996; Kobayashi et al., 1998; Li et al., 1998;
Tressler et al., 1999; Krüger et al., 2000; Lutz et al.,
2001), administration of this non-competitive antagonist
to tumor-bearing animals did also inhibited tumor
growth and metastasis.
In the present study, the synthetic peptide
cyclo19,31uPA19-31 was used as a lead structure to identify
more potent small molecule inhibitors of uPA/uPAR-inter-
action. Initially, we substituted each of the 13 L-amino
acids of peptide uPA19-31 individually by the correspon-
ding D-amino acid. Subsequently, cyclic counterparts of
those D-amino acid-containing peptides still displaying
distinct uPAR-binding capacities were generated. In ad-
dition, we also synthesised the retro-inverso variant of
cyclo19,31uPA19-31, substituted the cystin moiety in cy-
clo19,31uPA19-31 by lanthionine, and deleted the N- and C-
terminal cysteines, resulting in peptide cyclo20,30uPA20-30.
Finally, the most potent peptide, cyclo19,31[D-Cys19]-
uPA19-31, displaying an IC50 value of about 200 nM in flow
cytofluorometric analyses, was tested for its capacity to
displace uPAR-bound uPA from the cell surface of human
cells and to inhibit uPA-mediated, tumor cell-associated
plasminogen activation and fibrin degradation.
Results and Discussion
Stereochemical Modifications of uPA19-31
Substitution of L-amino acids by corresponding D-amino
acids in peptide analoga may yield additional information
with respect to the stereochemical basis for the genera-
tion of specific secondary structures and their input on
the interaction of the peptide ligand with its receptor. Fur-
thermore, since most proteases are enantio-specific, and
therefore do not cleave peptide bonds which are built up
by D-/L- or L-/D-amino acids, the use of D-amino acids
may also significantly improve the in vivo stability of such
peptide analoga. D-amino acids in peptide ligands may
also induce so-called ß-turns and, therefore, increase the
rigidity of structural motifs which are important for the
binding conformation.
We replaced each of the 13 L-amino acids of the linear
peptide uPA19-31 individually by the corresponding 
D-amino acid. After purification by HPLC, the ability of
these peptides to inhibit binding of fluorescently labeled
uPA to uPAR-expressing human U937 cells was tested
by flow cytofluorometry. The substitution of some 
L-amino acids by corresponding D-amino acids in uPA19-
31 (Asn22, Lys23, Tyr24, Phe25, Ser26, Ile28, and Cys31)
significantly reduced the binding capacities of these pep-
tide variants as compared to the parental peptide 
uPA19-31 (Table 1). This points to the fact that the stereo-
chemical orientation of these amino acids may be impor-
tant for binding or that certain D-amino acids induce a
structural change in the uPA19-31-variant, thereby leading
to a reduced interaction with uPAR. Interestingly, these
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amino acids –with the exception of Cys31 – are located in
the flexible Ω-loop of the uPAR-binding region of uPA.
Substitution of the L-amino acids Val20, Ser21, Asn27,
His29, Trp30, and, especially, Cys19, by the correspon-
ding D-enantiomers yielded peptide variants with distinct
uPAR-binding capacities. The linear peptide [D-Cys19]-
uPA19-31 inhibits the uPA/uPAR-interaction close in order to
that of the cyclic lead structure cyclo19,31uPA19-31 (Table 1).
Cyclic D-Amino Acid-Containing Variants of uPA19-31
Cyclic counterparts of the linear uPA19-31-derived pep-
tides that display an inhibitory activity towards uPA/uPAR-
interaction in the FACS analyses were generated, HPLC-
purified and again tested by FACS analysis. Substitution
of L-Cys by D-Cys at position 19 led to a distinct increase
of biological activity (Figure 1). The IC50 value of peptide
cyclo19,31[D-Cys19]-uPA19-31 to inhibit the interaction of
FITC-labeled uPA with uPAR was approx. 200 nM, that of
the lead peptide cyclo19,31-uPA19-31 about 700 nM. The IC50
value of both unlabelled human uPA and ATF was
5 – 10 nM. Thus, the binding affinity of the D-Cys19-modi-
fied uPA-peptide is only 20- to 40-fold lower than that of
the naturally occurring uPAR-ligands uPA and ATF.
Other Cyclic uPA-Derived Peptide Variants
In addition to the peptides with single D-amino acid sub-
stitutions, we generated a cyclic peptide in which all 
L-amino acids were substituted by their corresponding
D-enantiomers and in which all of the peptide bonds
were inverted. This approach resulted in the so-called
retro-inverso, protease-insensitive peptide of cyclo19,31-
uPA19-31 (Figure 2).
As initially proposed by Prelog and Gerlach (1964) and
Shemyakin et al. (1969), the complete inversion of all chi-
rality centers, together with the inversion of the amino
acid sequence should lead to a similar topochemical ori-
entation of the side chains than the parent peptide, pro-
vided the topology of the intramolecular hydrogen bonds
is neglected. Indeed, several groups have observed that
retroenantiomeric peptides may display comparable bio-
logical activities as the parent peptides (Chorev and
Goodman, 1993). In line with this, the structural evalua-
tion of a cyclic Fcε RI α-chain-derived peptide and its
retro-inverso motif by NMR showed similarity of the sur-
face topology of both compounds (McDonnell et al.,
1997). However, as demonstrated by Wermuth et al.
(1997), the topology of the αvβ3 integrin inhibitor cyclo
(–RGDfV–) and its retro-inverso peptide can differ, result-
ing in different activity profiles of the derivative or even
complete loss of biological activity.
The retro-inverso peptide of uPA19-31 did not show any
uPAR-binding activity (Figure 1). This may due to the fact
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Table 1 uPAR-Binding Characteristics of uPA19-31-Related
Synthetic Peptides.
Peptide Inhibition
Linear Cyclic
uPA19-31 +++ +++
[D-Cys19]-uPA19-31 +++ ++++
[D-Val20]-uPA19-31 ++ (+/–)
[D-Ser21]-uPA19-31 ++ ++
[D-Asn22]-uPA19-31 – n.t.
[D-Lys23]-uPA19-31 – n.t.
[D-Tyr24]-uPA19-31 – n.t.
[D-Phe25]-uPA19-31 – n.t.
[D-Ser26]-uPA19-31 – n.t.
[D-Asn27]-uPA19-31 ++ ++
[D-Ile28]-uPA19-31 (+/–) n.t.
[D-His29]-uPA19-31 ++ (+/–)
[D-Trp30]-uPA19-31 ++ (+/–)
[D-Cys31]-uPA19-31 (+/–) n.t.
Retro-inverso-uPA19-31 – –
[Ala19-S-Ala31]-uPA19-31 n.t. (+/–)
[D-Cys21,Hph25,Cys29]-uPA21-30 n.t. –
[Cys21,Ala24,Cys29]-uPA21-30 n.t. –
uPA20-30 – –
The uPAR-binding capacities of linear and cyclic uPA-derived
variants were tested by flow cytofluorometry. For this, PMA-
stimulated human U937 cells (2.5 × 105 cells per 250 µl) were co-
incubated with 16 ng FITC-pro-uPA and varying amounts of the
uPA-peptides, and the cell-associated fluorescence was deter-
mined. Key: ++++, efficient competition of FITC-pro-uPA bind-
ing with < 1 µg peptide; +++, efficient competition with < 2.5 µg;
++, about 50% competition with 2.5 µg; (+/–), weak inhibition of
FITC-pro-uPA binding with ≥ 10 µg peptide; –, no inhibition; n.t.,
not tested; Hph, homophenyl-alanine.
Fig. 1 Dose-Dependent Inhibition of Binding of Fluorescently
Labelled pro-uPA to Cell Surface-Associated uPAR by Cy-
clo19,31-uPA19-31 and Cyclo19,31[D-Cys19]-uPA19-31.
PMA-stimulated human U937 cells (2.5 × 105 cells per 250 µl)
were coincubated with 16 ng FITC-pro-uPA and increasing con-
centrations of synthetic cyclic uPA-derived peptides at room
temperature, and the cell-associated fluorescence determined.
Whereas cyclo19,31-uPA19-31 (IC50: approx. 700 nM) and cy-
clo19,31[D-Cys19]-uPA19-31 (IC50: approx. 200 nM) efficiently block
uPA/uPAR-interaction, the retro-inverso peptide of uPA19-31 (for
the primary structure see Figure 2) exerts no effect. The result is
representative of three independently performed experiments.
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that retro-D-peptides harbor exchanged N- and C-termi-
ni (Figure 2) and that these terminal groups in the peptide
cyclo19,31uPA19-31 are important for the interaction with
uPAR. Alternatively, the amide bonds in the backbone of
the peptide (which are reversed in the retro-inverso pep-
tide) may be necessary for the binding of the uPA-derived
peptide to uPAR. One also has to take into account that
the hydrogen bond pattern in retro-inverso peptides is
different as compared to the parental peptides.
To further elucidate the importance of Cys19 and
Cys31 in cyclic uPA-peptides for binding to uPAR, we
generated two other peptide variants: (i) cyclo20,30uPA20-30
was generated by the formation of a peptide bond of the
terminal -NH2 group of Val20 and the terminal -COOH
group of Trp30; (ii) cyclo19,31[Ala19-S-Ala31]-uPA19-31 corre-
sponds to a peptide variant of cyclo19,31-uPA19-31, in
which the cystine (Cys-Cys, which formally corresponds
to Ala19-S-S-Ala31) is substituted by lanthionine (Ala19-S-
Ala31).
This thioether analogue of the cystine is found in a vari-
ety of natural products, mainly in ‘lantibiotics’ such as
nisin, subtilin, and cinnamycin (Jung, 1991; Sahl et al.,
1995). The biosynthesis of the lanthionine peptides oc-
curs ribosomally by posttranslational stereoselective
Michael-like addition of cysteine to dehydroalanine and
always results in a D-configuration at the generated
asymmetric center (Sahl et al., 1995). Due to the increased
interest in lantibiotics in pharmaceutical research, server-
al routes to synthesise the mentioned thioether moiety
were examined. Among these are the Michael-type addi-
tion to dehydroalanines (Miller, 1980; Probert et al., 1996),
nucleophilic ring-opening of serine-ß-lactones (Shao et
al., 1995; Arnold et al., 1998), sulfur extrusions of protect-
ed peptides (Wakamiya et al., 1983), in situ alkylations of
immobilised peptidyl cysteine residues (Mayer et al.,
1998), and asymmetric alkylations of cysteines with 
ß-iodo-alanine derivatives (Dugave and Ménez, 1997). In
our hand, the last mentioned method worked best regard-
ing practical and chemical considerations.
In native human uPA, the distance between the Cα-
atoms of Cys19 and Cys31 (which are not connected by
a disulfide bond) is 6.1 Å (Hansen et al., 1994a, b), where-
as the average distance of cysteines engaged in disulfide
bridges (as in peptide cyclo19,3-uPA19-31) is about 5.2 Å.
The distance between the Cα-atoms at amino acid posi-
tions 19 and 31 is further narrowed down in
cyclo19,31[Ala19-S-Ala31]-uPA19-31 to about 4.8 Å. Cy-
clo19,31[Ala19-S-Ala31]-uPA19-31 displayed a distinct – but
compared to the parental peptide cyclo19,3-uPA19-31 sig-
nificantly lower – inhibitory activity with respect to inter-
ference with the uPA/uPAR-interaction (Table 1). This in-
dicates that the cystine-bridge in the lead uPA-peptide
structure could be modified by peptido-mimetica to
some extent.
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Fig. 2 Comparison of the Primary Structure of Retro-Inverso Cyclo19,31-uPA19-31 with Its Parental Peptide.
The differences between the two peptides are highlighted in the retro-inverso form. The sequence of cyclo19,31-uPA19-31 (with the disul-
fide bridge formed by Cys19 and Cys31) is: 19Cys-Val-Ser-Asn-Lys-Tyr-Phe-Ser-Asn-Ile-His-Trp-Cys31.
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In previous studies (Bürgle et al., 1997), we observed
that linear uPA19-31-derived peptides harboring Cys to
Ser substitutions ([Ser19]-uPA19-31; [Ser31]-uPA19-31;
[Ser19,Ser31]-uPA19-31) or even shorter peptides such as
uPA20-30 did not interact with uPAR. We now have extend-
ed these analyses by synthesising and testing cy-
clo20,30uPA20-30 and observed that this peptide – similar to
the above mentioned peptides – does not display any
uPAR binding capacity (Table 1).
Cyclo19,31[D-Cys19]-uPA19-31 Effectively Displaces
uPAR-Bound uPA from the Cell Surface
As shown in Figure 1, cyclo19,31[D-Cys19]-uPA19-31 effi-
ciently blocks binding of uPA to uPAR, when both the
peptide and the protease are added simultaneously to
uPAR-exposing human tumor cells. We also wanted
to know whether cyclo19,31[D-Cys19]-uPA19-31 will dis-
place uPA from cell surface-uPAR. Therefore, we at first
incubated promyeloid U937 cells (which were pre-treat-
ed under mild acid conditions to dissociate endoge-
nous receptor-bound uPA) with FITC-conjugated HMW-
uPA to allow binding to uPAR and, subsequently, added
increasing amounts of cyclo19,31[D-Cys19]-uPA19-31 to
the cells. As shown in Figure 3, cyclo19,31[D-Cys19]-
uPA19-31 – as well as unlabeled HMW-uPA – efficiently
reduced cell-associated fluorescence in a dose-de-
pendent manner. A cyclic control uPA-peptide, which
does not interact with uPAR (cyclo21,29[D-Cys21,
Hph25,Cys29]-uPA21-30; Table 1) had no effect on disso-
ciation.
Cyclo19,31[D-Cys19]-uPA19-31 Inhibits uPA-Mediated
Plasminogen Activation and Fibrin Degradation
To test whether cyclo19,31[D-Cys19]-uPA19-31 does inhibit
uPA-mediated plasminogen activation, we seeded uPA-
producing ovarian cancer cells (OV-MZ-6) in the pres-
ence of plasminogen onto fibrin clots. After 4 h of incuba-
tion, supernatants containing fibrin degradation products
(including D-dimer), produced via proteolytic action by
plasmin, were collected. As can be seen from Figure 4,
cyclo19,31[D-Cys19]-uPA19-31 efficiently reduces the gener-
ation of D-dimer in a dose-dependent manner. A cyclic
uPA-related control peptide, which does not interact with
uPAR (cyclo21,29[Cys21,Ala24,Cys29]-uPA21-30; Table 1) had
no effect. As controls, the amino-terminal fragment of
uPA (ATF), which also blocks binding of endogenously
produced uPA to the cell surface, or a monoclonal anti-
body directed against human uPA, which inhibits the pro-
teolytic activity of uPA, was employed. In both cases, a
significant reduction of uPA-mediated plasminogen acti-
vation and, in consequence, fibrin degradation was ob-
served (Figure 4).
Conclusions
Due to its important role in tumor-associated processes
the urokinase-type plasminogen activation system
emerged as an attractive target for anti-invasive and anti-
metastatic therapy. Over the past years, a variety of sub-
stances known to interfere with the expression or reactiv-
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Fig. 3 Displacement of uPAR-Bound, Fluorescently Labelled
HMW-uPA by Cyclo19,31[D-Cys19]-uPA19-31.
PMA-stimulated human U937 cells (2.5 × 105 cells per 250 µl)
were pre-incubated with 25 ng FITC-HMW-uPA, then in-
creasing concentrations of synthetic cyclic uPA-derived pep-
tides or unlabeled HMW-uPA were added (1 h, 37 °C) and,
subsequently, the cell-associated fluorescence was de-
termined. Whereas cyclo19,31[D-Cys19]-uPA19-31 and HMW-uPA
efficiently displace FITC-HMW-uPA from the cell surface,
a uPA-related peptide with no uPAR-binding activity (cy-
clo21,29 [D-Cys21,Hph25,Cys29]-uPA21-30) has no effect. The re-
sult is representative of three independently performed ex-
periments.
Fig. 4 Inhibition of Cell Surface-Associated uPA-Mediated
Plasminogen Activation and Fibrin Degradation by Cyclo19,31[D-
Cys19]-uPA19-31.
uPA-producing ovarian cancer cells (OV-MZ-6) were seeded on
fibrin gels in the presence of plasminogen (2 µg/ml medium) to-
gether with increasing amounts of synthetic peptides (2.5, 10
and 20 µM, respectively). As controls, either ATF (2 µg/ml medi-
um) or mAb # 394 directed against human uPA (10 µg/ml medi-
um) were added instead of the synthetic peptides. After 4 h, cell
culture supernatants were analysed for the presence of D-dimer
as the result of fibrin degradation by plasmin. Whereas cy-
clo19,31[D-Cys19]-uPA19-31 inhibits fibrin degradation in a dose-
dependent manner, a uPA-related peptide with no uPAR-binding
activity (cyclo21,29[Cys21,Ala24,Cys29]-uPA21-30) has no effect.
Both ATF and mAb # 394 also significantly inhibit D-dimer for-
mation. Mean values (± SD) are given for measurements per-
formed in duplicate.
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ity of uPA or uPAR at the gene or protein level were de-
veloped, including antisense oligodeoxynucleotides or
RNA (Wilhelm et al., 1995; Mohan et al., 1999), protease
inhibitors (Towle et al., 1993; Sperl et al., 2000), recombi-
nant soluble uPAR (Krüger et al., 2000; Lutz et al., 2001),
or uPA-derived antagonists of uPA/uPAR-interaction. In
the latter case, mostly large therapeutic molecules were
generated and tested in vivo. For example, it was demon-
strated that a uPA1-137/IgG-chimera suppressed the
metastatic capacity of human PC3 prostate carcinoma
cells in nude mice (Crowley et al., 1993). Similarly, reduc-
tion of growth of primary human breast carcinoma in im-
munodeficient mice was observed by administration of a
fusion protein consisting of human or murine uPA1-48
fused to the Fc portion of human IgG (Tressler et al.,
1999). A bifunctional inhibitor, consisting of uPA1-134
fused to domain II of the urinary trypsin inhibitor (UTI),
suppressed experimental tumor invasion and metastasis
by blocking uPA/uPAR-interaction via the amino-terminal
fragment of uPA within this chimeric molecule and by in-
hibition of plasmin activity via UTI (Kobayashi et al.,
1998). The application of large molecules to treat cancer
patients appears rather difficult and depends on sophis-
ticated, e. g. viral, delivery systems. Consequently, our
aim was to develop synthetic, small peptide inhibitors
derived from the continuous uPAR-binding sequence of
uPA (Magdolen et al., 1996; Bürgle et al., 1997). Using the
cyclic disulfide-bridged form of the minimal uPAR-bind-
ing region as lead structure (cyclo19,31uPA19-31), we have
identified cyclo19,31[D-Cys19]-uPA19-31 as – to our knowl-
edge – the most potent competitive uPA-antagonist
presently known that displays only a 20- to 40-fold lower
uPAR-binding capacity as compared to the natural uPAR
ligands uPA or ATF. Cyclo19,31[D-Cys19]-uPA19-31 inhibits
binding of uPA to uPAR on human tumor cells with more
than 3-fold higher efficiency compared to the lead struc-
ture and at least with 10-fold higher efficiency compared
to a high affinity uPAR ligand (clone 20 peptide) derived
from bacteriophage display (Goodson et al., 1994; Bürgle
et al., 1997). Furthermore, cyclo19,31[D-Cys19]-uPA19-31 ef-
ficiently displaces uPAR-bound uPA from the cell surface
of human cells and inhibits uPA-mediated, cell-associat-
ed plasminogen activation and fibrin degradation. We are
currently synthesising a series of cyclo19,31[D-Cys19]-
uPA19-31-variants, in which particular amino acids are
substituted by amino acids not occuring in natural pro-
teins (e. g. substitution of lysine by ornithine or nor-
leucine; tryptophan by 1-naphthyl- or 2-naphthyl-ala-
nine, etc.). This strategy may lead to high affinity
uPA-antagonists with increased biological availability
due to higher resistance against proteolytic degradation.
Recently, a synthetic non-competitive peptidic antago-
nist of the pro-uPA/uPAR-interaction, the Å6-peptide,
has been successfully tested in vivo. The administration
of Å6 – in a rather high concentration of 75 mg per kg per
day – resulted in a significant inhibition of tumor growth
and also suppressed the development of lymph node
metastases in both syngeneic (rat breast cancer) and
xenogeneic (human breast cancer in nude mice) tumor
model systems (Guo et al., 2000). Thus, high affinity com-
petitive antagonists of uPA/uPAR-interaction, such as cy-
clo19,31[D-Cys19]-uPA19 – 31 or variants thereof, may con-
stitute potent therapeutic agents for inhibition of tumor
growth and metastasis.
Materials and Methods
Solid-Phase Peptide Synthesis
Linear peptides were synthesised on a trityl polystyrene resin
(PepChem, Tübingen, Germany) using an Applied Biosystems
model 431A peptide synthesiser or a multiple peptide synthesis-
er, model SyRo II (MultiSynTech, Witten, Germany). Applying an
orthogonal Fmoc-strategy (Carpino and Han, 1972; Fields and
Noble, 1990), the amino acid side chains were protected with
trityl- (Asn, Cys, Gln, and His), tert-butyloxycarbonyl- (Lys and
Trp), tert-butyl (Asp, Glu, Ser, Thr, and Tyr), and 2,2,5,5,7,8-pen-
tamethylchroman-6-sulfonyl- or 2,2,4,6,7-pentamethyldihy-
drobenzofuran-5-sulfonyl (Arg) groups. Couplings were per-
formed twice for 1 h each at room temperature (RT) in NMP using
a 3-fold excess of 2-(1H-benzotriazole-1-yl)-1,1,3,3-tetramethy-
luronium tetrafluoroborate (TBTU)/1-hydroxybenzotriazole
(HOBt)/Fmoc-amino acid with 2.8 equivalents of N,N-diiso-
propylethylamine (DIEA) in NMP. The Fmoc-group was removed
by sequential treatment of the resins with an excess of 20%
piperidine in DMF for 5 and 15 min, respectively. Cleavage of the
peptides from the resins as well as removal of the side chain pro-
tecting groups, and work up was performed as follows (a and b,
respectively):
(a) treatment with 82.5% trifluoroacetic acid (TFA)/5% phe-
nol/2.5% ethanedithiol/5% thioanisol/5% H2O (0 ºC, 1 h; fol-
lowed by RT, 1 h). In the case of 2,2,5,5,7,8-pentamethylchro-
man-6-sulfonyl protected Arg, peptides were treated for
additional 12 h at RT. The crude peptides were precipitated in di-
ethylether at – 30 ºC, dissolved in methanol, precipitated as be-
fore, redissolved in tBuOH and then lyophilised. Tryptophan-
containing peptides were treated additionally with 5% AcOH for
2 h prior to lyophilisation (White, 1992). Peptides were purified
by HPLC using a Beckman Instruments System Gold or a Phar-
macia Biotech Series 900 with a reversed phase C-18 column
(Nucleosil 100 5-C18) or a YMC-Pack ODS/A column with H2O
and ACN plus 0.1% TFA as eluents applying an optimised gradi-
ent. Peptides cyclised via disulfide bridges were synthesised
from the linear precursors through oxidation as described under
(b).
(b) Treatment with 90% TFA/7% triisopropylsilane (TIPS)/3%
H2O (RT, 3 × 15 min). The solution was evaporated, the resulting
white solid powder suspended in H2O (0.1 – 0.3 mg/ml of the
crude peptide), cooled with ice and diluted with DMSO (end
concentration: 20% v/v). After 10 – 24 h the solvent was re-
moved under reduced pressure, the resulting white solid powder
dissolved in DMSO, diluted with an equal aliquot of H2O, filtered,
and purified by HPLC as described above.
Backbone cyclisation of uPA20-30 was performed as follows:
the N-terminally deprotected peptidyl-resin was treated with
75% DCM/12.5% trifluoroethanol (TFE)/12.5% AcOH (RT, 2 h)
and filtered. The resin was washed twice with DCM. The pooled
solutions were evaporated in the presence of toluene and the re-
sulting oil lyophilised from dioxane to yield a white powder. The
linear peptide was dissolved in dry DCM/DMF (7:3 v/v, 0.4 mM).
1,3-diisopropylcarbodiimide (DIC), N-methylmorpholine (NMM),
and 1-hydroxy-7-azabenzotriazole (HOAt) (1, 4, 2 equivalents,
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respectively) were added at 0 °C under vigorous stirring. The so-
lution was kept unstirred at 4 °C for 24 h when the completion of
the reaction was indicated by HPLC analysis. The solvents were
evaporated, the resulting oil dissolved in DCM, washed with
H2O, dried over Na2SO4 and the solvent then removed under re-
duced pressure. After lyophilisation from dioxane, side-chain
deprotection was achieved as described above (method b), fol-
lowed by HPLC purification.
Synthesis of cyclo19,31[Ala19-S-Ala31]-uPA19-31: the lanthionine
building block (R)-benzyl-N-triphenylmethylalanyl-(R)-methyl-
N-benzyloxycarbonylalanylsulfide was prepared from N-benzy-
loxycarbonyl-L-cysteinemethylester and N-triphenylmethyl-3-
iodo-L-alaninebenzyl-ester according to a procedure published
by Dugave and Ménez (1997). The suitable orthogonally protect-
ed (R)-benzyl-N-fluorenylmethyloxycarbonylalanyl-(R)-methyl-
N-benzyloxycarbonyl-alanylsulfide was prepared by deprotec-
tion (1.2 eq. LiOH in H2O/dioxane at pH 8 – 9, followed by
treatment with 50% TFA/DCM) and reprotection with 1.1 eq. 
N-(9-fluorenylmethyloxycarbonyl)oxysuccinimide (Fmoc-ONSu)/
DIEA, followed by flash chromatography over silica gel with an
optimised hexane/ethyl acetate gradient including AcOH con-
centrations ranging from 0 and 10%. This lanthionine deriva-
tive was coupled to H-Val-Ser(tBu)-Asn(Trt)-Lys(Boc)-Tyr(tBu)-
TCP as described above, followed by Fmoc deprotection,
coupling of Fmoc-Phe-Ser(tBu)-Asn(Trt)-Ile-His(Trt)-Trp(Boc)-
OH with 2-(1H-7-azabenzotriazol-1-yl)-1,1,3,3-tetramethy-
luronium hexafluorophosphate (HATU)/HOAt/sym-collidine (1,
1, 10 eq., respectively) and Fmoc deprotection. The resulting
peptide was cleaved from the resin, cyclised and side-chain
deprotected as described for the cyclo20,30uPA20-30. The result-
ing peptide cyclo19,31[L-Ala19(Z)-S-L-Ala31(OBn)]-uPA19-31
was purified by HPLC and completely deprotected by treat-
ment with 80% TFA, 10% trifluoromethanesulfonic acid
(TFMS), 5% TIPS and 5% m-cresole (RT, 30 min). Preparative
HPLC followed by lyophilisation from tBuOH yielded the de-
sired peptide as a white solid.
Mass spectrometric and amino acid analysis for characterisa-
tion and quantitation of the peptide concentration was per-
formed as described previously (Bürgle et al., 1997).
Flow Cytofluorometry
The capacity of synthetic peptides to inhibit uPA/uPAR-interac-
tion was assessed by FACS analysis with the FACScan flow
cytofluorometer (Becton-Dickinson, Heidelberg, Germany; low
power argon laser excitation at 488 nm) as described previously
(Chucholowski et al., 1992; Magdolen et al., 1996; Bürgle et al.,
1997). Briefly, human U937 cells - stimulated with phorbol-12-
myristate-13-acetate (PMA, 1 mM) for 48 h - were treated with
50 mM glycine-HCl, 0.1 M NaCl, pH 3.0, to dissociate endoge-
nous receptor-bound uPA (1 min, RT). Subsequently, the acidic
buffer was neutralised by an appropriate volume of 0.5 M HEPES/
100 mM NaCl, pH 7.5. The cells were washed, centrifuged and
resuspended in PBS/0.1% BSA (adjusted to 106 cells/ml). Sub-
sequently, the cells were incubated simultaneously with 16 ng
FITC-conjugated pro-uPA and varying amounts of the respec-
tive synthetic peptides in question (45 min, RT). Alternatively,
cells were pre-incubated with 25 ng FITC-labeled HMW-uPA
(15 min), before varying amounts of the respective synthetic
peptides or unlabeled HMW-uPA were added. In these displace-
ment studies, the fluorescence mean channel was determined
after 1 h incubation at 37 °C.
Fibrin Matrix Degradation Assay
Cell-associated plasminogen activation was assessed using a
fibrin degradation test as described previously (Reuning et al.,
1995). Briefly, fibrin gels were prepared in 24-well cell culture
plates by incubating 200 µl of 50 mg/ml plasminogen-depleted
fibrinogen (Calbiochem, Frankfurt, Germany), 50 µl of 150 mM
CaCl2, and 50 µl of 60 U/ml thrombin (Novagen, Schwalbach,
Germany) for 1 h at 37°C. uPA-producing ovarian cancer OV-
MZ-6 cells (Möbus et al., 1992; Fischer et al., 1998) were seeded
on top of the fibrin gel (4 × 104 cells/well) in the presence of plas-
minogen (2 µg/ml medium) and varying amounts of the respec-
tive synthetic uPA-peptides. As controls, the inhibitory mono-
clonal antibody against human uPA B-chain, mAb # 394
(10 µg/ml), or the amino-terminal fragment of uPA, ATF (2 µg/ml)
(both from American Diagnostica, Pfungstadt, Germany) were
used. After 4 h of incubation at 37°C, cell culture supernatants
were collected and analysed for the generation of fibrin degra-
dation products (including D-dimer) by ELISA (D-dimer test Gold
EIA kit #802, American Diagnostica).
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